{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:37:54Z","timestamp":1794335874073,"version":"4.9.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-030570"],"award-info":[{"award-number":["INV-030570"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["226137\/Z\/22\/Z"],"award-info":[{"award-number":["226137\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["226137\/Z\/22\/Z"],"award-info":[{"award-number":["226137\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["221003\/Z\/20\/Z"],"award-info":[{"award-number":["221003\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"U.S. Department of Health & Human Services | Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["6 U01IP001048"],"award-info":[{"award-number":["6 U01IP001048"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41591-024-03131-2","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T06:01:55Z","timestamp":1721973715000},"page":"2805-2812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["SARS-CoV-2 correlates of protection from infection against variants of concern"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-9884","authenticated-orcid":false,"given":"Kaiyuan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6354-4003","authenticated-orcid":false,"given":"Jinal N.","family":"Bhiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tempia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Kleynhans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimbai Sharon","family":"Madzorera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiniso","family":"Mkhize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haajira","family":"Kaldine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith L.","family":"McMorrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-0133","authenticated-orcid":false,"given":"Nicole","family":"Wolter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Moyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2717-5540","authenticated-orcid":false,"given":"Maimuna","family":"Carrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A.","family":"Martinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limakatso","family":"Lebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0003-0168","authenticated-orcid":false,"given":"Jacques D.","family":"du Toit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thulisa","family":"Mkhencele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-7455","authenticated-orcid":false,"given":"Anne","family":"von Gottberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3243-4711","authenticated-orcid":false,"given":"C\u00e9cile","family":"Viboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8719-4028","authenticated-orcid":false,"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0376-2302","authenticated-orcid":false,"given":"Cheryl","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PHIRST-C group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Buys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maimuna","family":"Carrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"de Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon","family":"du Plessis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"du Toit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc Xavier","family":"G\u00f3mez-Oliv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kgaugelo Patricia","family":"Kgasago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Retshidisitswe","family":"Kotane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith L.","family":"McMorrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tumelo","family":"Moloantoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tollman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"von Gottberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floidy","family":"Wafawanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Wolter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"3131_CR1","unstructured":"World Health Organization. Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. https:\/\/www.who.int\/news\/item\/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic (2023)."},{"key":"3131_CR2","unstructured":"World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https:\/\/covid19.who.int\/ (accessed 20 June 2024)."},{"key":"3131_CR3","unstructured":"World Health Organization. WHO COVID19 Vaccine Tracker. https:\/\/covid19.trackvaccines.org\/agency\/who\/ (accessed 20 June 2024)."},{"key":"3131_CR4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 22, 1293\u20131302 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"3131_CR5","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39098-w","volume":"14","author":"N Gozzi","year":"2023","unstructured":"Gozzi, N. et al. Estimating the impact of COVID-19 vaccine inequities: a modeling study. Nat. Commun. 14, 3272 (2023).","journal-title":"Nat. Commun."},{"key":"3131_CR6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s43856-022-00177-6","volume":"2","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Mapping global acceptance and uptake of COVID-19 vaccination: a systematic review and meta-analysis. Commun. Med. 2, 113 (2022).","journal-title":"Commun. Med."},{"key":"3131_CR7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41591-022-02185-4","volume":"29","author":"JV Lazarus","year":"2023","unstructured":"Lazarus, J. V. et al. A survey of COVID-19 vaccine acceptance across 23 countries in 2022. Nat. Med. 29, 366\u2013375 (2023).","journal-title":"Nat. Med."},{"key":"3131_CR8","doi-asserted-by":"crossref","first-page":"e1004107","DOI":"10.1371\/journal.pmed.1004107","volume":"19","author":"I Bergeri","year":"2022","unstructured":"Bergeri, I. et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: a systematic review and meta-analysis of standardized population-based studies. PLoS Med. 19, e1004107 (2022).","journal-title":"PLoS Med."},{"key":"3131_CR9","doi-asserted-by":"crossref","first-page":"e008793","DOI":"10.1136\/bmjgh-2022-008793","volume":"7","author":"HC Lewis","year":"2022","unstructured":"Lewis, H. C. et al. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. BMJ Glob. Health 7, e008793 (2022).","journal-title":"BMJ Glob. Health"},{"key":"3131_CR10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","volume":"608","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 608, 603\u2013608 (2022).","journal-title":"Nature"},{"key":"3131_CR11","volume":"14","author":"J Ito","year":"2023","unstructured":"Ito, J. et al. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. Nat. Commun. 14, 2671 (2023).","journal-title":"Nat. Commun."},{"key":"3131_CR12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"3131_CR13","first-page":"521","volume":"614","author":"Y Cao","year":"2023","unstructured":"Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 614, 521\u2013529 (2023).","journal-title":"Nature"},{"key":"3131_CR14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326 (2022).","journal-title":"Immunol. Rev."},{"key":"3131_CR15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"3131_CR16","volume":"14","author":"Y Fong","year":"2023","unstructured":"Fong, Y. et al. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat. Commun. 14, 331 (2023).","journal-title":"Nat. Commun."},{"key":"3131_CR17","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","volume":"7","author":"Y Fong","year":"2022","unstructured":"Fong, Y. et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat. Microbiol 7, 1996\u20132010 (2022).","journal-title":"Nat. Microbiol"},{"key":"3131_CR18","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040 (2021).","journal-title":"Nat. Med."},{"key":"3131_CR19","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"3131_CR20","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"3131_CR21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jinf.2023.07.007","volume":"87","author":"A Atti","year":"2023","unstructured":"Atti, A. et al. Antibody correlates of protection against Delta infection after vaccination: a nested case\u2013control within the UK-based SIREN study. J. Infect. 87, 420\u2013427 (2023).","journal-title":"J. Infect."},{"key":"3131_CR22","doi-asserted-by":"publisher","unstructured":"Zhang, B. et al. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.10.15.23295628 (2023).","DOI":"10.1101\/2023.10.15.23295628"},{"key":"3131_CR23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39816-4","volume":"14","author":"T Hertz","year":"2023","unstructured":"Hertz, T. et al. Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2. Nat. Commun. 14, 4575 (2023).","journal-title":"Nat. Commun."},{"key":"3131_CR24","doi-asserted-by":"crossref","first-page":"e2314757","DOI":"10.1001\/jamanetworkopen.2023.14757","volume":"6","author":"M Gilboa","year":"2023","unstructured":"Gilboa, M. et al. Factors associated with protection from SARS-CoV-2 Omicron variant infection and disease among vaccinated health care workers in Israel. JAMA Netw. Open 6, e2314757 (2023).","journal-title":"JAMA Netw. Open"},{"key":"3131_CR25","doi-asserted-by":"publisher","unstructured":"Maier, H. E. et al. An immune correlate of SARS-CoV-2 infection and severity of reinfections. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.11.23.21266767 (2021).","DOI":"10.1101\/2021.11.23.21266767"},{"key":"3131_CR26","doi-asserted-by":"crossref","first-page":"eadd4853","DOI":"10.1126\/sciimmunol.add4853","volume":"7","author":"J Tang","year":"2022","unstructured":"Tang, J. et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci. Immunol. 7, eadd4853 (2022).","journal-title":"Sci. Immunol."},{"key":"3131_CR27","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00654-6","volume":"8","author":"JM Knisely","year":"2023","unstructured":"Knisely, J. M. et al. Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report. NPJ Vaccines 8, 53 (2023).","journal-title":"NPJ Vaccines"},{"key":"3131_CR28","doi-asserted-by":"crossref","first-page":"e2314808120","DOI":"10.1073\/pnas.2314808120","volume":"120","author":"S Miyamoto","year":"2023","unstructured":"Miyamoto, S. et al. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection. Proc. Natl Acad. Sci. USA 120, e2314808120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3131_CR29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","volume":"21","author":"PV Markov","year":"2023","unstructured":"Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361\u2013379 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"3131_CR30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1473-3099(22)00069-X","volume":"22","author":"C Cohen","year":"2022","unstructured":"Cohen, C. et al. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21. Lancet Infect. Dis. 22, 821\u2013834 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"3131_CR31","volume":"14","author":"K Sun","year":"2023","unstructured":"Sun, K. et al. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa. Nat. Commun. 14, 246 (2023).","journal-title":"Nat. Commun."},{"key":"3131_CR32","doi-asserted-by":"crossref","first-page":"eabn4947","DOI":"10.1126\/science.abn4947","volume":"376","author":"JRC Pulliam","year":"2022","unstructured":"Pulliam, J. R. C. et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 376, eabn4947 (2022).","journal-title":"Science"},{"key":"3131_CR33","doi-asserted-by":"crossref","first-page":"eabo7081","DOI":"10.1126\/scitranslmed.abo7081","volume":"14","author":"K Sun","year":"2022","unstructured":"Sun, K. et al. SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron\u2019s impact in South African population cohorts. Sci. Transl. Med. 14, eabo7081 (2022).","journal-title":"Sci. Transl. Med."},{"key":"3131_CR34","unstructured":"Roche Diagnostics. Elecsys Anti-SARS-CoV-2. https:\/\/diagnostics.roche.com\/us\/en\/products\/params\/elecsys-anti-sars-cov-2.html (accessed June 20, 2024)."},{"key":"3131_CR35","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/cid\/ciy759","volume":"68","author":"BJ Cowling","year":"2019","unstructured":"Cowling, B. J. et al. Influenza hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection for influenza B. Clin. Infect. Dis. 68, 1713\u20131717 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"3131_CR36","first-page":"jiae122","volume":"7","author":"WW Lim","year":"2024","unstructured":"Lim, W. W., Shuo, F., Wong, S.-S., Sullivan, S. G. & Cowling, B. J. Hemagglutination inhibition antibody titers mediate influenza vaccine efficacy against symptomatic influenza A(H1N1), A(H3N2), and B\/Victoria infections. J. Infect. Dis. 7, jiae122 (2024).","journal-title":"J. Infect. Dis."},{"key":"3131_CR37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00001648-199503000-00010","volume":"6","author":"ME Halloran","year":"1995","unstructured":"Halloran, M. E. & Struchiner, C. J. Causal inference in infectious diseases. Epidemiology 6, 142\u2013151 (1995).","journal-title":"Epidemiology"},{"key":"3131_CR38","volume":"2","author":"KW Cohen","year":"2021","unstructured":"Cohen, K. W. et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep. Med. 2, 100354 (2021).","journal-title":"Cell Rep. Med."},{"key":"3131_CR39","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, eabf4063 (2021).","journal-title":"Science"},{"key":"3131_CR40","volume":"14","author":"TM Eser","year":"2023","unstructured":"Eser, T. M. et al. Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion. Nat. Commun. 14, 2952 (2023).","journal-title":"Nat. Commun."},{"key":"3131_CR41","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMc2209651","volume":"387","author":"S Havervall","year":"2022","unstructured":"Havervall, S. et al. Anti-spike mucosal IgA protection against SARS-CoV-2 Omicron infection. N. Engl. J. Med. 387, 1333\u20131336 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3131_CR42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","volume":"47","author":"SA Plotkin","year":"2008","unstructured":"Plotkin, S. A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47, 401\u2013409 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"3131_CR43","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","volume":"31","author":"DM Morens","year":"2023","unstructured":"Morens, D. M., Taubenberger, J. K. & Fauci, A. S. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host Microbe 31, 146\u2013157 (2023).","journal-title":"Cell Host Microbe"},{"key":"3131_CR44","doi-asserted-by":"crossref","first-page":"eadd9947","DOI":"10.1126\/sciimmunol.add9947","volume":"7","author":"EJ Topol","year":"2022","unstructured":"Topol, E. J. & Iwasaki, A. Operation Nasal Vaccine-Lightning speed to counter COVID-19. Sci. Immunol. 7, eadd9947 (2022).","journal-title":"Sci. Immunol."},{"key":"3131_CR45","unstructured":"US Department of Health and Human Services. Fact Sheet: HHS details $5 billion \u2018Project NextGen\u2019 initiative to stay ahead of COVID-19. https:\/\/aspr.hhs.gov\/newsroom\/Pages\/ProjectNextGen-May2023.aspx (accessed 20 June 2024)."},{"key":"3131_CR46","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3201\/eid2709.211042","volume":"27","author":"W Liu","year":"2021","unstructured":"Liu, W. et al. Predictors of nonseroconversion after SARS-CoV-2 infection. Emerg. Infect. Dis. 27, 2454\u20132458 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"3131_CR47","doi-asserted-by":"publisher","unstructured":"Lindeboom, R. G. H. et al. Human SARS-CoV-2 challenge uncovers local and systemic response dynamics. Nature https:\/\/doi.org\/10.1038\/s41586-024-07575-x (2024).","DOI":"10.1038\/s41586-024-07575-x"},{"key":"3131_CR48","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.abl8506","volume":"374","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science 374, 1621\u20131626 (2021).","journal-title":"Science"},{"key":"3131_CR49","doi-asserted-by":"crossref","DOI":"10.1126\/science.adj0070","volume":"382","author":"SH Wilks","year":"2023","unstructured":"Wilks, S. H. et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. Science 382, eadj0070 (2023).","journal-title":"Science"},{"key":"3131_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01911-2","author":"H Tegally","year":"2022","unstructured":"Tegally, H. et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-01911-2 (2022).","journal-title":"Nat. Med."},{"key":"3131_CR51","doi-asserted-by":"crossref","unstructured":"Fourati, S. et al. Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination. Nat. Immun. 23, 1777\u20131787 (2022).","DOI":"10.1038\/s41590-022-01329-5"},{"key":"3131_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01285-x","author":"CK Wibmer","year":"2021","unstructured":"Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01285-x (2021).","journal-title":"Nat. Med."},{"key":"3131_CR53","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.31.474032","author":"A Netzl","year":"2023","unstructured":"Netzl, A. et al. Analysis of SARS-CoV-2 Omicron neutralization data up to 2022-01-28. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.12.31.474032 (2023).","journal-title":"bioRxiv"},{"key":"3131_CR54","unstructured":"Cox, D. R. Planning of Experiments (Wiley, 1958)."},{"key":"3131_CR55","doi-asserted-by":"crossref","unstructured":"Imbens, G. W. & Rubin, D. B. Causal Inference in Statistics, Social, and Biomedical Sciences (Cambridge University Press, 2015).","DOI":"10.1017\/CBO9781139025751"},{"key":"3131_CR56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2307\/2530294","volume":"38","author":"IM Longini Jr","year":"1982","unstructured":"Longini, I. M. Jr & Koopman, J. S. Household and community transmission parameters from final distributions of infections in households. Biometrics 38, 115\u2013126 (1982).","journal-title":"Biometrics"},{"key":"3131_CR57","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1541-0420.2012.01757.x","volume":"68","author":"Y Yang","year":"2012","unstructured":"Yang, Y., Longini, I. M. Jr, Halloran, M. E. & Obenchain, V. A hybrid EM and Monte Carlo EM algorithm and its application to analysis of transmission of infectious diseases. Biometrics 68, 1238\u20131249 (2012).","journal-title":"Biometrics"},{"key":"3131_CR58","doi-asserted-by":"publisher","unstructured":"Kaiyuan, S. Data and code for SARS-CoV-2 correlates of protection from infection against variants of concern. Zenodo https:\/\/doi.org\/10.5281\/zenodo.11375487 (2024).","DOI":"10.5281\/zenodo.11375487"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03131-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03131-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03131-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T18:07:19Z","timestamp":1729102039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03131-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3131"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03131-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.28.24308095","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C. has received grant support from Sanofi Pasteur, the US Centers for Disease Control and Prevention, the Bill & Melinda Gates Foundation, the Taskforce for Global Health, the Wellcome Trust and the South African Medical Research Council. A.v.G. has received grant support from Sanofi Pasteur, Pfizer related to pneumococcal vaccine, the US Centers for Disease Control and Prevention and the Bill & Melinda Gates Foundation. N.W. reports grants from Sanofi Pasteur and the Bill & Melinda Gates Foundation. N.A.M. has received an institutional grant from Pfizer to conduct research in patients with pneumonia and from Roche to collect specimens to assess a novel tuberculosis assay. J.M. has received grant support from Sanofi Pasteur. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The PHIRST-C protocol was approved by the University of Witwatersrand Human Research Ethics Committee (ref. 150808), and the US Centers for Disease Control and Prevention\u2019s Institutional Review Board relied on the local review (no. 6840). The protocol was registered on ClinicalTrials.gov on 6 August 2015 and updated on 30 December 2020 (\n                      \n                      ). Participants receive grocery store vouchers of ZAR50 (USD 3) per visit to compensate for time required for specimen collection and interview. All participants provided written informed consent for study participation. For minors, consent was obtained from the parent or guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}